Previous 10 | Next 10 |
With the world facing inflationary and geopolitical hurdles, economic growth is poised to slow. Shares across sectors have been hit hard. Investors in growth stocks must identify companies with the right features to overcome headwinds to earnings. For further details see: ...
Cryoport is not just any biotech company, as it is banking on the booming logistic businesses for the cell/gene therapy sector. Leveraging the powerful merger and acquisition approach, Cryoport has been enjoying leaping top-line growth year-over-year. Despite a temporary setback, ...
The private sector balance decreased by over -$217+ billion in April 2022, pulling markets down with it. Credit creation from commercial banks was strong at $163B+. The seasonal pattern is down until early-to-mid May as the market negotiates a series of liquidity sinkholes from fe...
Shares of Cue Biopharma have tumbled some 75% since November 2021, as somewhat underwhelming data from slowly developing Phase 1 trials are at fault. The company’s Immuno-STAT platform is a novel approach to immuno-oncology that should reduce risks associated with systemic expo...
In a little over a year, the market has gone from sell "old economy", companies that make something and earn money, to sell companies that don’t make things and earn money. We are now at the stage where nobody cares. don’t buy anything, whether it makes makes "things" or...
Mitapivat got approved for PK deficiency. They have multiple label expansion potential. Current prices are attractively low. For further details see: Agios: Approved Product, Upcoming Catalysts
In a down market, you can pick up the same fundamentally robust companies at a fraction of their intrinsic value. As an orphan disease innovator, BioMarin is enjoying significant and substantial revenue increases from its approved assets. Nevertheless, the company is aggressively ...
Healthcare, Staples, and Utilities continue to outperform as selling intensifies in the growth style. Investor positioning is still light in the space – even after a year of alpha. While absolute valuations have turned somewhat pricey, the defensive supersector shows decent...
Biotech stocks had enjoyed strong hype and trajectories in the recent past, especially during the pandemic years. This is beginning to unravel. ETFs covering this sector have a massive preponderance of U.S. stocks, historically the most overvalued market in the world. As growth st...
DTIL has been lagging due to poor durability data. The company stock has been lagging due to market indifference. I see no prospects here. For further details see: Precision Bio: Another CAR-T Laggard With No Solid Prospects
News, Short Squeeze, Breakout and More Instantly...
iShares Biotechnology ETF Company Name:
IBB Stock Symbol:
NASDAQ Market:
2024-07-19 00:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-28 22:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...